NL1027811A1 - Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1. - Google Patents

Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.

Info

Publication number: NL1027811A1
Authority: NL; Netherlands
Prior art keywords: steroid; inhibitors; hydroxy; heterocyclic amines; dehydrogenase type
Prior art date: 2003-12-19

Application number

NL1027811A

Other languages

English (en)

Other versions

NL1027811C2 (nl

Inventor

Martin Paul Edwards

Theodore Otto Johnson Jr

Sajiv Krishnan Nair

Michael Siu

Wendy Dianne Taylor

Stephan James Cripps

Yong Wang

Hengmiao Cheng

Christopher Ronald Smith

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2004-12-17

Publication date

2005-06-21

2004-12-17 Application filed by Pfizer filed Critical Pfizer

2005-06-21 Publication of NL1027811A1 publication Critical patent/NL1027811A1/nl

2006-03-06 Application granted granted Critical

2006-03-06 Publication of NL1027811C2 publication Critical patent/NL1027811C2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)

NL1027811A 2003-12-19 2004-12-17 Heterocyclische aminen als remmers van 11-ß-hydroxy-steroïd-dehydrogenase type 1. NL1027811C2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US53118603P	2003-12-19	2003-12-19
US53118603		2003-12-19
US55692104P	2004-03-26	2004-03-26
US55692104		2004-03-26

Publications (2)

Publication Number	Publication Date
NL1027811A1 true NL1027811A1 (nl)	2005-06-21
NL1027811C2 NL1027811C2 (nl)	2006-03-06

Family

ID=34713786

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1027811A NL1027811C2 (nl)	2003-12-19	2004-12-17	Heterocyclische aminen als remmers van 11-ß-hydroxy-steroïd-dehydrogenase type 1.

Country Status (24)

Country	Link
US (1)	US20050148631A1 (nl)
EP (1)	EP1696915A1 (nl)
JP (1)	JP2007514731A (nl)
KR (1)	KR20060101772A (nl)
AP (1)	AP2006003633A0 (nl)
AR (1)	AR046767A1 (nl)
AU (1)	AU2004305321A1 (nl)
BR (1)	BRPI0417687A (nl)
CA (1)	CA2549651A1 (nl)
DO (1)	DOP2004001052A (nl)
EA (1)	EA200600990A1 (nl)
EC (1)	ECSP066653A (nl)
IL (1)	IL175949A0 (nl)
IS (1)	IS8473A (nl)
MA (1)	MA28271A1 (nl)
MX (1)	MXPA06007077A (nl)
NL (1)	NL1027811C2 (nl)
NO (1)	NO20063298L (nl)
OA (1)	OA13344A (nl)
PA (1)	PA8620301A1 (nl)
PE (1)	PE20050864A1 (nl)
TW (1)	TW200530185A (nl)
UY (1)	UY28674A1 (nl)
WO (1)	WO2005060963A1 (nl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7880001B2 (en)	2004-04-29	2011-02-01	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en)	2004-04-29	2010-09-02	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en)	2004-04-29	2013-04-09	Abbott Laboratories	Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
US8071624B2 (en)	2004-06-24	2011-12-06	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
BRPI0515931A (pt)	2004-09-29	2008-08-12	Hoffmann La Roche	compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
CN101035762B (zh) *	2004-10-04	2010-09-29	霍夫曼-拉罗奇有限公司	用于糖尿病的作为11-β抑制剂的烷基(alkil)-吡啶类
EP1659113A1 (en) *	2004-11-08	2006-05-24	Evotec AG	Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
AU2006203918B2 (en)	2005-01-05	2011-05-19	Abbvie Inc.	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
CA2594098C (en)	2005-01-05	2014-04-01	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en)	2005-01-05	2009-07-30	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en)	2005-01-05	2012-06-12	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006095822A1 (ja) *	2005-03-11	2006-09-14	Ono Pharmaceutical Co., Ltd.	スルホンアミド化合物およびその医薬
JP5140577B2 (ja)	2005-03-31	2013-02-06	タケダカリフォルニアインコーポレイテッド	ヒドロキシステロイドデヒドロゲナーゼ阻害剤
WO2006106423A2 (en) *	2005-04-07	2006-10-12	Pfizer Inc.	Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2527337A1 (en) *	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
DE602006010546D1 (de) *	2005-06-16	2009-12-31	Pfizer	N-(pyridin-2-yl)sulfonamidderivate
EP1922068A4 (en) *	2005-08-16	2010-08-11	Icagen Inc	INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
US7622492B2 (en)	2005-08-31	2009-11-24	Hoffmann-La Roche Inc.	Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
AU2006304283B2 (en)	2005-10-12	2012-01-19	Vertex Pharmaceuticals Incorporated	Biphenyl derivatives as modulators of voltage gated ion channels
WO2007067504A2 (en)	2005-12-05	2007-06-14	Incyte Corporation	Lactam compounds and methods of using the same
US20090018118A1 (en) *	2005-12-29	2009-01-15	Uros Urleb	Heterocyclic compounds
WO2007084314A2 (en)	2006-01-12	2007-07-26	Incyte Corporation	MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
AU2007207055B2 (en)	2006-01-18	2011-06-02	F. Hoffmann-La Roche Ag	Thiazoles as 11 beta-HSD1 inhibitors
TW200804341A (en) *	2006-01-31	2008-01-16	Incyte Corp	Amido compounds and their use as pharmaceuticals
WO2007114763A1 (en) *	2006-03-31	2007-10-11	Astrazeneca Ab	Sulphonamide derivates as modulators of the glucocorticoid receptor
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2018378A2 (en)	2006-05-17	2009-01-28	Incyte Corporation	Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
TW200827346A (en)	2006-11-03	2008-07-01	Astrazeneca Ab	Chemical compounds
TW200829578A (en)	2006-11-23	2008-07-16	Astrazeneca Ab	Chemical compounds 537
MX2009005279A (es) *	2006-11-24	2009-05-28	Ac Immune Sa	Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JO2754B1 (en)	2006-12-21	2014-03-15	استرازينكا ايه بي	Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200836719A (en)	2007-02-12	2008-09-16	Astrazeneca Ab	Chemical compounds
GB0705400D0 (en)	2007-03-21	2007-05-02	Univ Aberdeen	Therapeutic compounds andm their use
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
JP5736098B2 (ja)	2007-08-21	2015-06-17	アッヴィ・インコーポレイテッド	中枢神経系障害を治療するための医薬組成物
UY31832A (es)	2008-05-20	2010-01-05	Astrazeneca Ab	Derivados de indazol sustituidos con fenilo y benzodioxinilo
GB0817208D0 (en)	2008-09-19	2008-10-29	Pimco 2664 Ltd	Therapeutic apsap compounds and their use
GB0817207D0 (en)	2008-09-19	2008-10-29	Pimco 2664 Ltd	therapeutic apsac compounds and their use
ES2350077B1 (es)	2009-06-04	2011-11-04	Laboratorios Salvat, S.A.	Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
DE102010033690A1 (de) *	2010-08-06	2012-02-09	Saltigo Gmbh	Verfahren zur Herstellung vom Aminoarylalkylverbindungen
UA112418C2 (uk)	2010-09-07	2016-09-12	Астеллас Фарма Інк.	Терапевтичний болезаспокійливий засіб
US9233946B2 (en)	2010-09-17	2016-01-12	Kancera Ab	Sulfonamide compounds
WO2012124744A1 (ja) *	2011-03-14	2012-09-20	大正製薬株式会社	含窒素縮合複素環化合物
US10000449B2 (en)	2011-12-22	2018-06-19	Kancera Ab	Bisarylsulfonamides useful in the treatment of inflammation and cancer
KR102047816B1 (ko) *	2011-12-22	2019-11-22	칸세라 아베	염증 및 암 치료에 유용한 비스아릴술폰아미드
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
GB201311361D0 (en)	2013-06-26	2013-08-14	Pimco 2664 Ltd	Compounds and their therapeutic use
EP3027590A1 (en) *	2013-07-31	2016-06-08	Minoryx Therapeutics S.L.	Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
EP2940022B1 (en) *	2014-04-30	2020-09-02	Masarykova Univerzita	Furopyridines as inhibitors of protein kinases
CN107108508B (zh)	2014-12-17	2020-09-01	皮姆科2664有限公司	N-(4-羟基-4-甲基-环己基)-4-苯基-苯磺酰胺和n-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)-苯磺酰胺化合物及其治疗用途
EP3235813A1 (en)	2016-04-19	2017-10-25	Cidqo 2012, S.L.	Aza-tetra-cyclo derivatives
EP3735404B1 (en)	2018-01-02	2023-11-29	Seal Rock Therapeutics, Inc.	Ask1 inhibitor compounds and uses thereof
MX2021005801A (es)	2018-11-20	2021-08-05	Sparrow Pharmaceuticals Inc	Metodos para administrar corticosteroides.
AU2020378009A1 (en) *	2019-11-05	2022-05-26	Dermira, Inc.	MrgprX2 antagonists and uses thereof
IL316907A (en)	2022-05-16	2025-01-01	Sparrow Pharmaceuticals Inc	METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
WO2025117672A1 (en) *	2023-12-01	2025-06-05	Hotspot Therapeutics, Inc.	Indazolyl-piperidine sulfonamides and related compounds and their use in therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0472053B1 (en) *	1990-08-20	1998-06-17	Eisai Co., Ltd.	Sulfonamide derivatives
DE4041780A1 (de) *	1990-12-24	1992-06-25	Boehringer Mannheim Gmbh	Neue amine, verfahren zu ihrer herstellung, sowie diese verbindungen enthaltende arzneimittel
SE9103397D0 (sv) *	1991-11-18	1991-11-18	Kabi Pharmacia Ab	Nya substituerade salicylsyror
GB9504854D0 (en) *	1994-03-31	1995-04-26	Zeneca Ltd	Nitrogen derivatives
GB9409618D0 (en) *	1994-05-13	1994-07-06	Zeneca Ltd	Pyridine derivatives
WO1996036595A1 (en) *	1995-05-19	1996-11-21	Chiroscience Limited	3,4-disubstituted-phenylsulphonamides and their therapeutic use
US5939451A (en) *	1996-06-28	1999-08-17	Hoffmann-La Roche Inc.	Use of sulfonamides
GB9805520D0 (en) *	1998-03-17	1998-05-13	Zeneca Ltd	Chemical compounds
JP4327915B2 (ja) *	1998-03-30	2009-09-09	株式会社デ・ウエスタン・セラピテクス研究所	スルフォンアミド誘導体
ES2273725T3 (es) *	1999-09-04	2007-05-16	Astrazeneca Ab	Derivados de hidroxiacetamidobencenosulfonamida.
US6506754B1 (en) *	2000-04-14	2003-01-14	Corvas International, Inc.	Non-covalent thrombin inhibitors
SE0001899D0 (sv) *	2000-05-22	2000-05-22	Pharmacia & Upjohn Ab	New compounds
EA200400707A1 (ru) *	2001-11-22	2004-10-28	Биовитрум Аб	Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
IL161154A0 (en) *	2001-11-22	2004-08-31	Biovitrum Ab	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP2399903A1 (en) *	2002-05-24	2011-12-28	Millennium Pharmaceuticals, Inc.	Ccr9 inhibitors and methods of use thereof
WO2004056744A1 (en) *	2002-12-23	2004-07-08	Janssen Pharmaceutica N.V.	Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
AU2004240885A1 (en) *	2003-05-21	2004-12-02	Biovitrum Ab	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I

2004
- 2004-12-06 JP JP2006544581A patent/JP2007514731A/ja active Pending
- 2004-12-06 WO PCT/IB2004/004056 patent/WO2005060963A1/en not_active Ceased
- 2004-12-06 BR BRPI0417687-1A patent/BRPI0417687A/pt not_active IP Right Cessation
- 2004-12-06 MX MXPA06007077A patent/MXPA06007077A/es not_active Application Discontinuation
- 2004-12-06 KR KR1020067012036A patent/KR20060101772A/ko not_active Ceased
- 2004-12-06 EP EP04801352A patent/EP1696915A1/en not_active Withdrawn
- 2004-12-06 EA EA200600990A patent/EA200600990A1/ru unknown
- 2004-12-06 AP AP2006003633A patent/AP2006003633A0/xx unknown
- 2004-12-06 AU AU2004305321A patent/AU2004305321A1/en not_active Abandoned
- 2004-12-06 OA OA1200600201A patent/OA13344A/en unknown
- 2004-12-06 CA CA002549651A patent/CA2549651A1/en not_active Abandoned
- 2004-12-10 PE PE2004001240A patent/PE20050864A1/es not_active Application Discontinuation
- 2004-12-15 AR ARP040104669A patent/AR046767A1/es unknown
- 2004-12-16 UY UY28674A patent/UY28674A1/es not_active Application Discontinuation
- 2004-12-16 DO DO2004001052A patent/DOP2004001052A/es unknown
- 2004-12-17 NL NL1027811A patent/NL1027811C2/nl not_active IP Right Cessation
- 2004-12-17 PA PA20048620301A patent/PA8620301A1/es unknown
- 2004-12-17 TW TW093139461A patent/TW200530185A/zh unknown
- 2004-12-17 US US11/016,152 patent/US20050148631A1/en not_active Abandoned
2006
- 2006-05-18 IS IS8473A patent/IS8473A/is unknown
- 2006-05-25 IL IL175949A patent/IL175949A0/en unknown
- 2006-06-16 EC EC2006006653A patent/ECSP066653A/es unknown
- 2006-06-19 MA MA29114A patent/MA28271A1/fr unknown
- 2006-07-17 NO NO20063298A patent/NO20063298L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20050148631A1 (en)	2005-07-07
PE20050864A1 (es)	2005-10-31
BRPI0417687A (pt)	2007-04-03
DOP2004001052A (es)	2005-06-30
EA200600990A1 (ru)	2006-10-27
AP2006003633A0 (en)	2006-06-30
CA2549651A1 (en)	2005-07-07
MA28271A1 (fr)	2006-11-01
TW200530185A (en)	2005-09-16
WO2005060963A1 (en)	2005-07-07
NO20063298L (no)	2006-09-14
UY28674A1 (es)	2005-07-29
AR046767A1 (es)	2005-12-21
ECSP066653A (es)	2006-10-25
JP2007514731A (ja)	2007-06-07
AU2004305321A1 (en)	2005-07-07
WO2005060963A8 (en)	2005-12-01
IS8473A (is)	2006-05-18
KR20060101772A (ko)	2006-09-26
NL1027811C2 (nl)	2006-03-06
IL175949A0 (en)	2006-10-05
OA13344A (en)	2007-04-13
EP1696915A1 (en)	2006-09-06
PA8620301A1 (es)	2005-08-04
MXPA06007077A (es)	2006-08-23

Publication	Publication Date	Title
NL1027811A1 (nl)	2005-06-21	Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
CY2016042I1 (el)	2017-03-15	Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DE602004008303D1 (de)	2007-09-27	Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
IS7599A (is)	2004-12-15	Heterósýklískir kínasatálmar
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de)	2008-08-15	Diazepinoindolderivate als kinaseinhibitoren
NO20043642L (no)	2004-08-31	Heterocykiske tripeptider som hepatitt C inhibitorer
DE602004017623D1 (de)	2008-12-18	N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
DK2039685T3 (da)	2013-03-25	Heterobicycliske forbindelser som P38-inhibitorer
DE60315516D1 (de)	2007-09-20	Pyridazinon-derivate als cdk2-hemmer
IS8483A (is)	2006-05-26	Heterósýklísk virk efni gegn mígreni
DE602005011795D1 (de)	2009-01-29	Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DK1699455T3 (da)	2013-08-05	Heterocykliske aspartylproteasehæmmere
ATE404537T1 (de)	2008-08-15	Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
DK1534290T3 (da)	2012-04-10	Hidtil ukendte kinasehæmmere
DE602004025258D1 (de)	2010-03-11	Aminotriazol-verbindungen als proteinkinase-hemmer
ATE525377T1 (de)	2011-10-15	Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE602004018837D1 (de)	2009-02-12	Ptidase-iv-inhibitoren
DE602004012154D1 (de)	2008-04-10	Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
ATE401893T1 (de)	2008-08-15	Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
DE602004019555D1 (de)	2009-04-02	Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE402700T1 (de)	2008-08-15	Glycinamid-derivate als raf-kinase-hemmer
ATE538787T1 (de)	2012-01-15	Benzimidazol-derivative als raf-kinase-hemmer
ATE308325T1 (de)	2005-11-15	Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
NO20054854D0 (no)	2005-10-20	Femrings heterocykliske derivater

Legal Events

Date	Code	Title	Description
2005-09-01	AD1A	A request for search or an international type search has been filed
2006-01-02	RD2N	Patents in respect of which a decision has been taken or a report has been made (novelty report)	Effective date: 20051028
2006-05-01	PD2B	A search report has been drawn up
2009-09-01	VD1	Lapsed due to non-payment of the annual fee	Effective date: 20090701